{"schema":"hottub-news/list/v1","item_schema":"hottub-news/item/v1","count":39,"next":"https://hottub.news/v1/items?before=1790727739.794772&entity=Q818846","sponsored":0,"items":[{"id":"n_x4mr3k77k3sv66b3wraq","seq":1559300,"kind":"article","title":"Novo Nordisk Plans Denecimib U.S. Launch In H1 2027 Amid FDA Review Extension","url":"https://www.rttnews.com/3696255/novo-nordisk-plans-denecimib-u-s-launch-in-h1-2027-amid-fda-review-extension.aspx","published":"2026-10-03T13:12:00Z","seen":"2026-10-03T16:23:19Z","lang":"en","source":{"id":"rttnews.com","name":"rttnews.com","domain":"rttnews.com","outlet":{"wikidata":"Q60748698","name":"RTTNews","type":"news_agency","designations":["news agency","news website"]}},"via":"gdelt-gkg-english","topics":["economy"],"entities":[{"id":"Q818846","name":"Novo","type":"org"},{"id":"Q204711","name":"United States Food and Drug Administration","type":"org"}],"story":"st_x4mr3k77k3sv66b3wraq","category":"health","category_p":0.35,"category2":"economy-business","sentiment":"neutral","tone":0.06,"political":0.18},{"id":"n_a44plw52yae7ga4yjq2q","seq":1521947,"kind":"article","title":"Vice de Nunes se descola de Flávio e faz campanhas para candidatos do Novo e padre Kelmon","title_en":"Vice de Nunes separates from Flavio and campaigns for Novo candidates and Father Kelmon","url":"https://redir.folha.com.br/redir/online/emcimadahora/rss091/*https://www1.folha.uol.com.br/colunas/painel/2026/10/vice-de-nunes-se-descola-de-flavio-e-faz-campanhas-para-candidatos-do-novo-e-padre-kelmon.shtml","summary":"Descolado do grupo político do senador Flávio Bolsonaro (PL-RJ) , o vice-prefeito de São Paulo , Ricardo Mello Araújo (PL), tem se dedicado à divulgação de três candidatos a deputado, sendo dois deles filiados ao Novo, e o Padre Kelmon (PL). Leia mais (10/03/2026 - 07h50)","published":"2026-10-03T10:50:00Z","seen":"2026-10-03T11:14:33Z","lang":"pt","country":"BR","source":{"id":"kite-folha-uol-com-br-a7488b","name":"folha.uol.com.br","domain":"feeds.folha.uol.com.br"},"via":"kite-folha-uol-com-br-a7488b","authors":["author"],"entities":[{"id":"Q11199207","name":"FLAVIO","type":"person"},{"id":"Q818846","name":"Novo","type":"org"}],"story":"st_a44plw52yae7ga4yjq2q","category":"politics","category_p":0.75,"sentiment":"neutral","tone":0.01,"political":0.61},{"id":"n_7g4gvyxl45xfpmv6lqlq","seq":1447685,"kind":"article","title":"Dr. Praeger's, Novo Nordisk, Kings Food Markets cut New Jersey jobs","url":"https://nj1015.com/october-2026-nj-layoffs","published":"2026-10-02T22:44:00Z","seen":"2026-10-02T23:30:43Z","lang":"en","source":{"id":"nj1015.com","name":"nj1015.com","domain":"nj1015.com","outlet":{"wikidata":"Q7952036","name":"WKXW","type":"broadcaster","country":"US","designations":["radio station"]}},"via":"gdelt-gkg-english","topics":["economy","health","politics"],"authors":["Erin Vogt"],"entities":[{"id":"Q818846","name":"Novo","type":"org"},{"id":"Q6412914","name":"Kings Food Markets","type":"org"}],"story":"st_7g4gvyxl45xfpmv6lqlq","category":"economy-business","category_p":0.56,"sentiment":"negative","tone":-0.49,"political":0.14},{"id":"n_tjvsyukejirfdojcr33q","seq":1442112,"kind":"article","title":"Novo provides update on the denecimig Biologics License Application (BLA) in the US | Company Announcement","url":"https://www.investegate.co.uk/announcement/gnw/novo-nordisk-a-s-class-b--0qiu/novo-provides-update-on-the-denecimig-biologi-/9805200","published":"2026-10-02T22:30:00Z","seen":"2026-10-02T22:37:13Z","lang":"en","country":"GB","source":{"id":"investegate.co.uk","name":"investegate.co.uk","domain":"investegate.co.uk"},"via":"gdelt-gkg-english","topics":["economy","health","business"],"authors":["Investegate"],"entities":[{"id":"Q818846","name":"Novo","type":"org"}],"story":"st_o2no533midrniyykbepa","category":"economy-business","category_p":0.56,"sentiment":"neutral","tone":0.08,"political":0.08},{"id":"n_3ppyqoid6eagruf5ca2a","seq":1463815,"kind":"article","title":"Novo Nordisk Says FDA Review of Hemophilia Drug Is Hitting Delays","url":"https://www.morningstar.com/news/dow-jones/202610027099/novo-nordisk-says-fda-review-of-hemophilia-drug-is-hitting-delays","published":"2026-10-02T22:28:00Z","seen":"2026-10-03T02:20:37Z","lang":"en","source":{"id":"morningstar.com","name":"morningstar.com","domain":"morningstar.com","outlet":{"wikidata":"Q1389504","name":"Morningstar, Inc.","type":"other","country":"US","designations":["business","database","pinnacle financial solutions ltd","public company"]}},"via":"gdelt-gkg-english","topics":["economy"],"entities":[{"id":"Q818846","name":"Novo","type":"org"},{"id":"Q204711","name":"United States Food and Drug Administration","type":"org"}],"story":"st_3ppyqoid6eagruf5ca2a","category":"health","category_p":0.52,"sentiment":"neutral","tone":-0.15,"political":0.14},{"id":"n_55pz5rgj3em2sdrkhgla","seq":1437034,"kind":"article","title":"Novo provides update on the denecimig Biologics License Application (BLA) in the US","url":"https://www.manilatimes.net/2026/10/03/tmt-newswire/globenewswire/novo-provides-update-on-the-denecimig-biologics-license-application-bla-in-the-us/2438267","published":"2026-10-02T21:10:00Z","seen":"2026-10-02T21:52:31Z","lang":"en","source":{"id":"manilatimes.net","name":"manilatimes.net","domain":"manilatimes.net","outlet":{"wikidata":"Q1573100","name":"The Manila Times","type":"magazine","country":"PH","designations":["organization","periodical"]}},"via":"gdelt-gkg-english","topics":["economy","business","health"],"entities":[{"id":"Q818846","name":"Novo","type":"org"}],"story":"st_o2no533midrniyykbepa","category":"science-technology","category_p":0.33,"category2":"economy-business","sentiment":"neutral","tone":0.06,"political":0.15},{"id":"n_xdbovr6emyat7p52vtva","seq":1435705,"kind":"article","title":"Novo Nordisk Strikes Nearly $4 Billion in 2 Deals. Here's What That Means for Investors","url":"https://www.fool.com/investing/2026/10/02/novo-nordisk-strikes-nearly-usd4-billion-in-2-deals-here-s-what-that-means-for-investors?source=iedfolrf0000001","published":"2026-10-02T20:01:00Z","seen":"2026-10-02T21:39:16Z","lang":"en","source":{"id":"fool.com","name":"fool.com","domain":"fool.com","outlet":{"wikidata":"Q7752442","name":"The Motley Fool","type":"other","country":"US","designations":["dot-com company"]}},"via":"gdelt-gkg-english","authors":["Prosper Junior Bakiny"],"entities":[{"id":"Q818846","name":"Novo","type":"org"}],"story":"st_xdbovr6emyat7p52vtva","category":"economy-business","category_p":0.98,"sentiment":"positive","tone":0.38,"political":0.07},{"id":"n_ampiqtggtcdwdqla4pfa","seq":1416472,"kind":"article","title":"Com Zema sem fôlego, Novo se preocupa com possibilidade de ficar sem cadeiras na Alesp","title_en":"With Zema out of breath, Novo is concerned about the possibility of being left without seats in the Alesp","url":"https://veja.abril.com.br/politica/com-zema-sem-folego-novo-se-preocupa-com-possibilidade-de-ficar-sem-cadeiras-na-alesp","summary":"Sem puxador de voto e com seus nomes mais conhecidos fazendo campanha para outros partidos, Novo corre risco de não eleger deputados estaduais em São Paulo","published":"2026-10-02T18:30:03Z","seen":"2026-10-02T19:30:02Z","lang":"pt","country":"BR","source":{"id":"kite-veja-abril-com-br-1ec380","name":"veja.abril.com.br","domain":"veja.abril.com.br","outlet":{"wikidata":"Q1886657","name":"Veja","type":"magazine","country":"BR","designations":["magazine","news website"]}},"via":"kite-veja-abril-com-br-1ec380","topics":["política","assembleia legislativa","partido novo","radar","são paulo"],"authors":["Marcelo Ribeiro"],"entities":[{"id":"Q16532067","name":"Zema","type":"person"},{"id":"Q818846","name":"Novo","type":"person"},{"id":"Q4808730","name":"Legislative Assembly of São Paulo","type":"org"}],"image":"https://veja.abril.com.br/wp-content/uploads/2023/11/leonardo-siqueira.jpg","story":"st_ampiqtggtcdwdqla4pfa","category":"sport","category_p":0.37,"sentiment":"negative","tone":-0.46,"political":0.09},{"id":"n_7pmtz7heb4ul2qtodmwa","seq":1410673,"kind":"article","title":"Novo Nordisk (NYSE: NVO) Wegovy Clears Liver Fat To Normal Levels In Nearly 9 Out Of 10 Obese Adults In STEP UP Trial Analysis","url":"https://www.foreignpolicyjournal.com/2026/10/02/novo-nordisk-nyse-nvo-wegovy-clears-liver-fat-to-normal-levels-in-nearly-9-out-of-10-obese-adults-in-step-up-trial-analysis","published":"2026-10-02T16:30:00Z","seen":"2026-10-02T18:37:17Z","lang":"en","source":{"id":"foreignpolicyjournal.com","name":"foreignpolicyjournal.com","domain":"foreignpolicyjournal.com","outlet":{"wikidata":"Q140053273","name":"Foreign Policy Journal","type":"newspaper","country":"US","designations":["online newspaper"]}},"via":"gdelt-gkg-english","topics":["economy","business","health","education"],"authors":["Ewan Scott"],"entities":[{"id":"Q818846","name":"Novo","type":"org"},{"id":"Q133859283","name":"Wegovy","type":"other"}],"story":"st_7pmtz7heb4ul2qtodmwa","category":"health","category_p":0.6,"sentiment":"positive","tone":-0.26,"political":0.01},{"id":"n_xjyovxvoqxw2z6cjdttq","seq":1414195,"kind":"article","title":"Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?","url":"https://www.fool.com/coverage/better-buy/2026/10/02/novo-nordisk-vs-pfizer-which-healthcare-stock-is-a-better-buy-in-2026?source=iedfolrf0000001","published":"2026-10-02T16:15:00Z","seen":"2026-10-02T18:51:33Z","lang":"en","source":{"id":"fool.com","name":"fool.com","domain":"fool.com","outlet":{"wikidata":"Q7752442","name":"The Motley Fool","type":"other","country":"US","designations":["dot-com company"]}},"via":"gdelt-gkg-english","topics":["economy"],"authors":["Brendan Coffey"],"entities":[{"id":"Q818846","name":"Novo","type":"org"},{"id":"Q206921","name":"Pfizer","type":"org"}],"story":"st_axccl6ppkcznstgtnmhq","category":"economy-business","category_p":0.61,"category2":"health","sentiment":"neutral","tone":-0.11,"political":0.03},{"id":"n_xhwqj7bwb422xogy24sq","seq":1372494,"kind":"article","title":"Participants Taking CagriSema Showed Changed Brain Responses to High-Calorie Food Images in Novo Study as FDA Decision Nears","url":"https://www.medicaldaily.com/cagrisema-brain-scan-food-noise-fda-decision-479416","summary":"Novo says brain scans showed CagriSema changed food-cue responses and cut cravings. The data are early, and an FDA decision is expected in late 2026.","published":"2026-10-02T13:30:07Z","seen":"2026-10-02T15:07:28Z","lang":"en","source":{"id":"kite-medicaldaily-com-05fda3","name":"medicaldaily.com","domain":"medicaldaily.com","outlet":{"wikidata":"Q69052919","name":"Medical Daily","type":"website","country":"US","designations":["website"]}},"via":"kite-medicaldaily-com-05fda3","topics":["medicine"],"entities":[{"id":"Q123427726","name":"cagrilintide/semaglutide","type":"other"},{"id":"Q818846","name":"Novo","type":"org"},{"id":"Q204711","name":"United States Food and Drug Administration","type":"org"}],"mentions":2,"story":"st_xhwqj7bwb422xogy24sq","category":"health","category_p":0.78,"sentiment":"neutral","tone":0.11,"political":0.04},{"id":"n_gowx3wbmdkbbi5xh6ktq","seq":1349571,"kind":"article","title":"Novo sænker prisen på Wegovy: Visse patienter kan spare hundredvis","title_en":"Novo lowers the price of Wegovy: Certain patients can save hundreds","url":"https://nyheder24.dk/sundhed/novo-saenker-prisen-paa-wegovy-visse-patienter-kan-spare-hundredvis","summary":"Novo ændrer nu prisen på Wegovy, men det er ikke alle, der får glæde af det","published":"2026-10-02T12:45:00Z","seen":"2026-10-02T13:15:38Z","lang":"da","country":"DK","source":{"id":"kite-nyheder24-dk-57a0f2","name":"nyheder24.dk","domain":"nyheder24.dk","outlet":{"wikidata":"Q136365716","name":"Nyheder24.dk","type":"website","country":"DK","designations":["news website"]}},"via":"kite-nyheder24-dk-57a0f2","topics":["sundhed","novo nordisk","wegovy"],"authors":["Alberte Clausen"],"entities":[{"id":"Q818846","name":"Novo","type":"org"},{"id":"Q133859283","name":"Wegovy","type":"other"}],"image":"https://media.mgdk.dk/wp-content/uploads/sites/2/2025/09/wegovy.webp","story":"st_7utkydksvifosayly2na","category":"health","category_p":0.49,"category2":"economy-business","sentiment":"positive","tone":0.45,"political":0.04},{"id":"n_jvab7lj7nenaomcoou2a","seq":1347563,"kind":"article","title":"Novo Nordisk: Es geht es um viel mehr als die Abnehmspritze","title_en":"Novo Nordisk: It's about much more than the weight-loss injection","url":"https://www.faz.net/aktuell/wirtschaft/unternehmen/novo-nordisks-wette-auf-die-zukunft-nach-ozempic-201278172.html","summary":"Das dänische Pharmaunternehmen geht in die Produktoffensive und will sich breiter aufstellen. Warum die Wegovy-Pille ein wichtiger Trumpf bleibt und welche Rolle Telemedizin spielt.","published":"2026-10-02T12:40:55Z","seen":"2026-10-02T13:02:11Z","lang":"de","country":"DE","source":{"id":"kite-faz-net-d53f4c","name":"faz.net","domain":"faz.net","outlet":{"wikidata":"Q10184","name":"Frankfurter Allgemeine Zeitung","type":"newspaper","country":"DE","designations":["daily newspaper","organization"]}},"via":"kite-faz-net-d53f4c","authors":["Maybrit Martschin"],"entities":[{"id":"Q818846","name":"Novo","type":"org"}],"image":"https://media0.faz.net/image/b8b1158bfd9b/w5472h3078x0y159/202606/43601.0.2226414241/wegovy-pille-novo-plant.webp","story":"st_jvab7lj7nenaomcoou2a","category":"health","category_p":0.69,"sentiment":"neutral","tone":0.1,"political":0.07},{"id":"n_o2nmtvdoh5cork6li7aq","seq":1300140,"kind":"article","title":"Olesen (Novo): \"Vogliamo essere simbolo di prevenzione\"","title_en":"Olesen (Novo): 'We want to be a symbol of prevention'","url":"https://www.adnkronos.com/cronaca/olesen-novo-vogliamo-essere-simbolo-di-prevenzione_3BMOyyMtyEq8clgdAcSRBG","summary":"(Adnkronos) - 'Prendersi cura dei più vulnerabili nella società è l'esempio di ciò che facciamo'","published":"2026-10-02T08:17:49Z","seen":"2026-10-02T08:47:41Z","lang":"it","country":"IT","source":{"id":"kite-adnkronos-com-b8794c","name":"adnkronos.com","domain":"adnkronos.com","outlet":{"wikidata":"Q359875","name":"Adnkronos","type":"news_agency","country":"IT","designations":["news agency","publishing house"]}},"via":"kite-adnkronos-com-b8794c","topics":["cronaca"],"authors":["author"],"entities":[{"id":"Q141583356","name":"Olesen","type":"person"},{"id":"Q818846","name":"Novo","type":"org"}],"image":"https://www.adnkronos.com/resources/02aa-21bab9edc2f8-8216e92d94fa-1000/format/medium/olesen.jpeg","story":"st_o2nmtvdoh5cork6li7aq","category":"sport","category_p":0.21,"sentiment":"neutral","tone":0.27,"political":0.06},{"id":"n_kaugx2cvapymw7qip4za","seq":1300142,"kind":"article","title":"Hicken (Novo): \"Prevenzione importante quanto la cura\"","title_en":"Hicken (Novo): 'Prevention is as important as care'","url":"https://www.adnkronos.com/cronaca/hicken-novo-prevenzione-importante-quanto-la-cura_4eLH0GjjEztIWdQOoZk7B2","summary":"(Adnkronos) - 'È importante essere uniti per promuovere la prevenzione e l'inclusione'","published":"2026-10-02T08:16:20Z","seen":"2026-10-02T08:47:41Z","lang":"it","country":"IT","source":{"id":"kite-adnkronos-com-b8794c","name":"adnkronos.com","domain":"adnkronos.com","outlet":{"wikidata":"Q359875","name":"Adnkronos","type":"news_agency","country":"IT","designations":["news agency","publishing house"]}},"via":"kite-adnkronos-com-b8794c","topics":["cronaca"],"authors":["author"],"entities":[{"id":"Q5555788","name":"Cristóbal María Hicken","type":"person"},{"id":"Q818846","name":"Novo","type":"org"}],"image":"https://www.adnkronos.com/resources/02aa-21bab9665d35-587628dd1ba7-1000/format/medium/hicken.jpeg","story":"st_kaugx2cvapymw7qip4za","category":"health","category_p":0.87,"sentiment":"neutral","tone":0.06,"political":0.04},{"id":"n_ujakzbcxfxu5xfedfzga","seq":1297279,"kind":"article","title":"Thomas Bernt med opsang til Novo-medarbejdere i krisetid: »Hvis det vigtigste vilkår er at redde virksomheden hjemmefra, så er samtalen brudt sammen«","title_en":"Thomas Bernt with a song for Novo employees in crisis: 'If the main condition is to save the company from home, then the conversation has broken down'","url":"https://www.berlingske.dk/samfund/thomas-bernt-med-opsang-til-novo-medarbejdere-i-krisetid-hvis-det-vigtigste-vilkaar-er-at-redde-virksomheden-hjemmefra-saa-er-samtalen-brudt-sammen?referrer=RSS","summary":"Novo er på en ny rejse under ledelse af topchef Mike Doustdar. Og der er brug for at skære medicinalgiganten til og stille flere krav, mener Berlingskes erhvervskommentator.","published":"2026-10-02T07:52:11Z","seen":"2026-10-02T08:30:22Z","lang":"da","country":"DK","source":{"id":"kite-berlingske-dk-a0a3d7","name":"berlingske.dk","domain":"berlingske.dk","outlet":{"wikidata":"Q59055","name":"Berlingske","type":"newspaper","country":"DK","designations":["daily newspaper","newspaper","weekly newspaper"]}},"via":"kite-berlingske-dk-a0a3d7","topics":["samfund"],"authors":["author"],"entities":[{"id":"Q818846","name":"Novo","type":"org"}],"image":"https://akamai-aptoma-production.bmcdn.dk/users/berlingske/images/163262680.webp?accessToken=21605434ce033a413d0306cb882f9975a7d05dacaaa0ee9a65cc34333ec360ef&t[quality]=70&t[strip]=true","story":"st_ujakzbcxfxu5xfedfzga","category":"politics","category_p":0.23,"sentiment":"negative","tone":-0.49,"political":0.31},{"id":"n_2hdfe4hc6ejwqujlucfa","seq":1265225,"kind":"article","title":"Novo sięga po nowy lek na otyłość. Może być przyjmowany raz w tygodniu","title_en":"Novo reaches for a new obesity drug. It can be taken once a week","url":"https://www.bankier.pl/wiadomosc/Novo-siega-po-nowy-lek-na-otylosc-Moze-byc-przyjmowany-raz-w-tygodniu-9206011.html","summary":"Novo kupuje od największej chińskiej firmy farmaceutycznej prawa do eksperymentalnego leku na cukrzycę i otyłość, który potencjalnie można będzie przyjmować tylko raz w tygodniu.","published":"2026-10-02T04:44:41Z","seen":"2026-10-02T04:44:41Z","lang":"pl","country":"PL","source":{"id":"kite-bankier-pl-99b9dc","name":"bankier.pl","domain":"bankier.pl","outlet":{"wikidata":"Q11687313","name":"Q11687313","type":"other","country":"PL","designations":["commercial organization"]}},"via":"kite-bankier-pl-99b9dc","entities":[{"id":"Q818846","name":"Novo","type":"org"}],"story":"st_2hdfe4hc6ejwqujlucfa","category":"health","category_p":0.56,"category2":"economy-business","sentiment":"neutral","tone":0.11,"political":0.04},{"id":"n_ped5wuqyut36yoyeboja","seq":1257704,"kind":"article","title":"Novo vil nå ud til nye målgrupper med Wegovy-pille","title_en":"Novo will reach new target groups with Wegovy pill","url":"https://www.bt.dk/erhverv/novo-vil-naa-ud-til-nye-maalgrupper-med-wegovy-pille?referrer=RSS","summary":"Med Wegovy-pillen kan Novo nå dem, som ikke vil ses som patienter, siger Novo-direktør.","published":"2026-10-02T03:30:45Z","seen":"2026-10-02T03:44:00Z","lang":"da","country":"DK","source":{"id":"kite-bt-dk-3131ee","name":"bt.dk","domain":"bt.dk","outlet":{"wikidata":"Q327821","name":"B.T.","type":"newspaper","designations":["daily newspaper"]}},"via":"kite-bt-dk-3131ee","topics":["erhverv","nyheder"],"entities":[{"id":"Q818846","name":"Novo","type":"org"},{"id":"Q133859283","name":"Wegovy","type":"other"}],"image":"https://akamai-aptoma-production.bmcdn.dk/users/berlingske/images/163265749.webp?accessToken=d06feb0bf1a95b6e72700b4f4803d789aa78de07f351f637464d2a5885c07854&t[quality]=70&t[strip]=true","story":"st_xloyorybdn2xd7areoza","category":"health","category_p":0.31,"category2":"economy-business","sentiment":"neutral","tone":0.22,"political":0.2},{"id":"n_mdhms7jgzwggbnjjjckq","seq":1180273,"kind":"article","title":"Novo Nordisk får kritik efter ulovlige reklamer for vægtabtsmedicin","title_en":"Novo Nordisk receives criticism after illegal advertisements for weight loss medication","url":"https://www.tv2kosmopol.dk/metropolen/novo-nordisk-far-kritik-efter-ulovlige-reklamer-for-vaegtabtsmedicin-346f1","summary":"Novo Nordisk har brudt loven fire gange i år. Det vurderer Lægemiddelstyrelsen i to nye afgørelser. Det skriver DR. Ifølge styrelsen har Novo i tre af tilfældene reklameret ulovligt for vægttabsmedicin direkte på LinkedIn. De tre opslag, som Novo nu har slettet fra platformen. I det fjerde tilfælde er der kritik om brud på loven med et patientprogram om vægttab, som Novo har lavet sammen med Falck. Samarbejdet er nu stoppet , og Novo har fået en bøde af Etisk Nævn for…","published":"2026-10-01T16:07:00Z","seen":"2026-10-01T17:01:03Z","lang":"da","country":"DK","source":{"id":"kite-tv2kosmopol-dk-7a626e","name":"tv2kosmopol.dk","domain":"tv2kosmopol.dk","outlet":{"wikidata":"Q12338663","name":"TV 2 Kosmopol","type":"broadcaster","country":"DK","designations":["broadcaster","online newspaper","television station"]}},"via":"kite-tv2kosmopol-dk-7a626e","entities":[{"id":"Q818846","name":"Novo","type":"org"}],"story":"st_pljtqadewdybta37qbxa","category":"health","category_p":0.44,"category2":"economy-business","sentiment":"negative","tone":-0.76,"political":0.25},{"id":"n_pljtqadewdybta37qbxa","seq":1151324,"kind":"article","title":"Novo får kritik for flere ulovlige reklamer for vægttabsmedicin","title_en":"Novo receives criticism for several illegal advertisements for weight loss medication","url":"https://www.dr.dk/nyheder/indland/novo-faar-kritik-flere-ulovlige-reklamer-vaegttabsmedicin","summary":"Medicinalgiganten er uenig i afgørelserne. Alligevel har Novo fjernet det ulovlige indhold.","published":"2026-10-01T14:00:00Z","seen":"2026-10-01T14:27:36Z","lang":"da","country":"DK","source":{"id":"kite-dr-dk-906d07","name":"dr.dk","domain":"dr.dk","outlet":{"wikidata":"Q1164334","name":"DR","type":"public_broadcaster","country":"DK","designations":["organization","production company","public broadcaster"]}},"via":"kite-dr-dk-906d07","entities":[{"id":"Q818846","name":"Novo","type":"org"}],"image":"https://asset.dr.dk/drdk/umbraco-images/g4bb25ua/20260921-142820-6.jpg?im=AspectCrop=(1200,675),xPosition=.5,yPosition=.5;Resize=(1200,675)&impolicy=medium","mentions":2,"story":"st_pljtqadewdybta37qbxa","category":"health","category_p":0.38,"category2":"crime-law","sentiment":"negative","tone":-0.8,"political":0.37},{"id":"n_smgtpxui6xhs5uoo6agq","seq":1119644,"kind":"article","title":"Novo Nordisk A/S: Novo's Wegovy (semaglutide) reduced liver fat to normal levels in 9 out of 10 adults with obesity and excess liver fat","url":"https://www.finanznachrichten.de/nachrichten-2026-10/69729661-novo-nordisk-a-s-novo-s-wegovy-semaglutide-reduced-liver-fat-to-normal-levels-in-9-out-of-10-adults-with-obesity-and-excess-liver-fat-easd2026-399.htm","published":"2026-10-01T11:11:43Z","seen":"2026-10-01T11:11:43Z","lang":"en","country":"DE","source":{"id":"finanznachrichten.de","name":"finanznachrichten.de","domain":"finanznachrichten.de","outlet":{"wikidata":"Q1408247","name":"Finanznachrichten.de","type":"website","designations":["website"]}},"via":"gdelt-gkg-english","topics":["economy","education","health"],"authors":["GlobeNewswire (Europe)"],"entities":[{"id":"Q818846","name":"Novo","type":"org"},{"id":"Q133859283","name":"Wegovy","type":"other"},{"id":"Q27261089","name":"semaglutide","type":"other"}],"story":"st_kyrlx6rfgk3l53fn4tua","category":"health","category_p":0.78,"sentiment":"positive","tone":-0.19,"political":0.01},{"id":"n_kyrlx6rfgk3l53fn4tua","seq":1119015,"kind":"article","title":"Novo's Wegovy® (semaglutide) reduced liver fat to normal levels in 9 out of 10 adults with obesity and excess liver fat - EASD2026","url":"https://www.manilatimes.net/2026/10/01/tmt-newswire/globenewswire/novos-wegovy-semaglutide-reduced-liver-fat-to-normal-levels-in-9-out-of-10-adults-with-obesity-and-excess-liver-fat-easd2026/2436936","published":"2026-10-01T10:58:00Z","seen":"2026-10-01T11:11:43Z","lang":"en","source":{"id":"manilatimes.net","name":"manilatimes.net","domain":"manilatimes.net","outlet":{"wikidata":"Q1573100","name":"The Manila Times","type":"magazine","country":"PH","designations":["organization","periodical"]}},"via":"gdelt-gkg-english","topics":["economy","health","education"],"entities":[{"id":"Q818846","name":"Novo","type":"org"},{"id":"Q133859283","name":"Wegovy","type":"other"}],"story":"st_kyrlx6rfgk3l53fn4tua","category":"health","category_p":0.75,"sentiment":"positive","tone":-0.15,"political":0.01},{"id":"n_doye63ik2mgf7zk7gbua","seq":1082967,"kind":"article","title":"Novo sänker priset på Wegovy i Sverige","title_en":"Novo lowers the price of Wegovy in Sweden","url":"https://www.dagensmedicin.se/alla-nyheter/lakemedel/novo-sanker-priset-pa-wegovy-i-sverige","summary":"Läkemedelsjätten Novo sänker priset på viktläkemedlet Wegovy med 20 procent på den svenska marknaden. Samtidigt pågår företagets process för att läkemedlet ska subventioneras.","published":"2026-10-01T05:53:34Z","seen":"2026-10-01T08:13:56Z","lang":"sv","source":{"id":"kite-dagensmedicin-se-9a1f28","name":"dagensmedicin.se","domain":"dagensmedicin.se","outlet":{"wikidata":"Q10465894","name":"Dagens Medicin","type":"newspaper","country":"SE","designations":["news website","newspaper","periodical"]}},"via":"kite-dagensmedicin-se-9a1f28","topics":["medicine"],"entities":[{"id":"Q818846","name":"Novo","type":"org"}],"image":"https://static.bonniernews.se/ba/ecea2cda-be22-4d9f-bb96-e48add4f53f2.jpg?crop=6000%2C3375%2Cx0%2Cy313","story":"st_7utkydksvifosayly2na","category":"economy-business","category_p":0.8,"sentiment":"neutral","tone":0.11,"political":0.05},{"id":"n_7utkydksvifosayly2na","seq":1063668,"kind":"article","title":"Glada Asienbörser – Novo sänker priset på Wegovy i Sverige","title_en":"Happy Asian markets – Novo lowers the price of Wegovy in Sweden","url":"https://www.di.se/ditv/morgonkoll/glada-asienborser-novo-sanker-priset-pa-wegovy-i-sverige","summary":"Morgonens viktigaste nyheter med Rushd Massad","published":"2026-10-01T05:46:24Z","seen":"2026-10-01T06:08:43Z","lang":"sv","country":"SE","source":{"id":"kite-di-se-755352","name":"di.se","domain":"di.se","outlet":{"wikidata":"Q734293","name":"Dagens Industri","type":"newspaper","designations":["newspaper"]}},"via":"kite-di-se-755352","entities":[{"id":"Q818846","name":"Novo","type":"org"}],"story":"st_7utkydksvifosayly2na","category":"economy-business","category_p":0.96,"sentiment":"positive","tone":0.47,"political":0.03},{"id":"n_g27miwx2ltdbhdir7nva","seq":1055645,"kind":"article","title":"Novo sänker priset på viktläkemedlet i Sverige","title_en":"Novo lowers the price of the weight loss drug in Sweden","url":"https://www.dagensps.se/privatekonomi/novo-sanker-priset-pa-viktlakemedlet-i-sverige","summary":"Från och med den 1 oktober genomförs prissänkningen. Enligt bolaget ska prissänkningen innebära en besparing på omkring 500 kronor i månaden för patienter, förutsatt att apoteken sänker sina försäljningspriser i samma omfattning. Läkemedelsjätten Novo sänker priset på viktläkemedlet Wegovy med 20 procent på den svenska marknaden. Samtidigt pågår företagets process för att läkemedlet ska subventioneras. […]","published":"2026-10-01T05:03:14Z","seen":"2026-10-01T05:10:03Z","lang":"sv","country":"SE","source":{"id":"kite-dagensps-se-4df340","name":"dagensps.se","domain":"dagensps.se","outlet":{"wikidata":"Q10465892","name":"Q10465892","type":"magazine","designations":["online magazine"]}},"via":"kite-dagensps-se-4df340","topics":["privatekonomi"],"authors":["TT Nyhetsbyrån"],"entities":[{"id":"Q818846","name":"Novo","type":"org"}],"image":"https://images.dagensps.se/app/uploads/2026/10/wegovy-tillverkas-av-novo-arkivbild.jpg","story":"st_khh2nznrvuu6o3xypvja","category":"economy-business","category_p":0.74,"category2":"health","sentiment":"neutral","tone":0.13,"political":0.07},{"id":"n_xv32dvitilul4uro63jq","seq":1051556,"kind":"article","title":"Novo cuts Wegovy price by 20% in Sweden as subsidy bid continues","url":"https://swedenherald.com/article/novo-cuts-wegovy-price-by-20-in-sweden-as-subsidy-bid-continues","summary":"Pharmaceutical giant Novo is cutting the price of its weight loss drug Wegovy by 20 percent on the Swedish market. At the same time, the company is working to get the drug subsidized.","published":"2026-10-01T04:00:13Z","seen":"2026-10-01T04:30:04Z","lang":"en","country":"SE","source":{"id":"kite-swedenherald-com-9145a8","name":"swedenherald.com","domain":"swedenherald.com","outlet":{"wikidata":"Q132131820","name":"Sweden Herald","type":"newspaper","designations":["online newspaper"]}},"via":"kite-swedenherald-com-9145a8","topics":["business news"],"authors":["Sweden Herald"],"entities":[{"id":"Q818846","name":"Novo","type":"org"},{"id":"Q133859283","name":"Wegovy","type":"other"}],"image":"https://static.swedenherald.com/99d44caa-6e7e-4819-a012-2084cd3c5c05/99d44caa-6e7e-4819-a012-2084cd3c5c05.jpg","story":"st_xv32dvitilul4uro63jq","category":"economy-business","category_p":0.94,"sentiment":"positive","tone":0.24,"political":0.19},{"id":"n_lozatvhmwjyffx6veeaq","seq":1026860,"kind":"article","title":"Novo Is Open to Acquisitions. Here Are 2 Companies That Would Be Great Candidates to Buy","url":"https://www.fool.com/investing/2026/09/30/novo-is-open-to-acquisitions-here-are-2-companies?source=iedfolrf0000001","published":"2026-09-30T23:10:00Z","seen":"2026-10-01T00:35:26Z","lang":"en","source":{"id":"fool.com","name":"fool.com","domain":"fool.com","outlet":{"wikidata":"Q7752442","name":"The Motley Fool","type":"other","country":"US","designations":["dot-com company"]}},"via":"gdelt-gkg-english","topics":["economy","health","business"],"authors":["Prosper Junior Bakiny"],"entities":[{"id":"Q818846","name":"Novo","type":"org"}],"story":"st_lozatvhmwjyffx6veeaq","category":"economy-business","category_p":0.92,"sentiment":"neutral","tone":0.31,"political":0.02},{"id":"n_46bd6mjvtquhk5hiulra","seq":989792,"kind":"article","title":"Novo Nordisk (NYSE: NVO) Ozempic 2 mg Linked To Lower Heart Attack And Stroke Risk Versus Switching To Mounjaro In Real-World Study","url":"https://www.foreignpolicyjournal.com/2026/09/30/novo-nordisk-nyse-nvo-ozempic-2-mg-linked-to-lower-heart-attack-and-stroke-risk-versus-switching-to-mounjaro-in-real-world-study","published":"2026-09-30T17:35:00Z","seen":"2026-09-30T20:08:08Z","lang":"en","source":{"id":"foreignpolicyjournal.com","name":"foreignpolicyjournal.com","domain":"foreignpolicyjournal.com","outlet":{"wikidata":"Q140053273","name":"Foreign Policy Journal","type":"newspaper","country":"US","designations":["online newspaper"]}},"via":"gdelt-gkg-english","topics":["economy","health","science","business"],"authors":["Ewan Scott"],"entities":[{"id":"Q818846","name":"Novo","type":"org"},{"id":"Q47521958","name":"Ozempic","type":"other"},{"id":"Q108324770","name":"tirzepatide","type":"other"}],"story":"st_lbpcbvmwoukdjkwtr7aq","category":"health","category_p":0.81,"sentiment":"neutral","tone":-0.18,"political":0.02},{"id":"n_jqoyluvwqyx4y6n3v75q","seq":952120,"kind":"article","title":"Novo Nordisk CagriSema Cuts \"Food Noise\", Shows Organ And Bone Health Benefits","url":"https://www.rttnews.com/3695434/novo-nordisk-cagrisema-cuts-food-noise-shows-organ-and-bone-health-benefits.aspx","published":"2026-09-30T16:04:00Z","seen":"2026-09-30T16:21:53Z","lang":"en","source":{"id":"rttnews.com","name":"rttnews.com","domain":"rttnews.com","outlet":{"wikidata":"Q60748698","name":"RTTNews","type":"news_agency","designations":["news agency","news website"]}},"via":"gdelt-gkg-english","topics":["economy","health"],"entities":[{"id":"Q818846","name":"Novo","type":"org"}],"story":"st_nika56zngf2cerq2cc3a","category":"health","category_p":0.64,"sentiment":"positive","tone":0.15,"political":0.03},{"id":"n_lqm7udfllloau523cpaa","seq":937326,"kind":"article","title":"Could This Company Challenge Eli Lilly and Novo Nordisk in the Weight Loss Market?","url":"https://www.aol.com/articles/could-company-challenge-eli-lilly-144401000.html","published":"2026-09-30T14:44:00Z","seen":"2026-09-30T15:23:34Z","lang":"en","source":{"id":"aol.com","name":"aol.com","domain":"aol.com","outlet":{"wikidata":"Q27585","name":"AOL","type":"website","country":"US","designations":["business","company","enterprise","media company","online service provider","search engine","web portal"]}},"via":"gdelt-gkg-english","topics":["economy","health","business"],"authors":["AOL"],"entities":[{"id":"Q2984214","name":"Eli Lilly","type":"org"},{"id":"Q818846","name":"Novo","type":"org"}],"story":"st_et23qkz3l4wf7sbdhxuq","category":"economy-business","category_p":0.82,"sentiment":"neutral","tone":0.11,"political":0.0},{"id":"n_g5fkhfllt3ed3nlrnuna","seq":907114,"kind":"article","title":"Novo's investigational obesity and diabetes drug CagriSema reduces 'food noise' and shows benefits in organ and bone health – EASD 2026 | Company Announcement","url":"https://www.investegate.co.uk/announcement/gnw/novo-nordisk-a-s-class-b--0qiu/novo-s-investigational-obesity-and-diabetes-d-/9799444","published":"2026-09-30T12:52:37Z","seen":"2026-09-30T12:52:37Z","lang":"en","country":"GB","source":{"id":"investegate.co.uk","name":"investegate.co.uk","domain":"investegate.co.uk"},"via":"gdelt-gkg-english","topics":["science","health","economy","business"],"authors":["Investegate"],"entities":[{"id":"Q818846","name":"Novo","type":"org"},{"id":"Q61523534","name":"chanoclavine-I dehydrogenase easD","type":"event"}],"story":"st_nika56zngf2cerq2cc3a","category":"health","category_p":0.61,"category2":"economy-business","sentiment":"positive","tone":0.09,"political":0.04},{"id":"n_gqdcahaxuwe6dxzc7pkq","seq":907710,"kind":"article","title":"Novo's investigational obesity and diabetes drug CagriSema reduces 'food noise' and shows benefits in organ and bone health - EASD 2026","url":"https://www.manilatimes.net/2026/09/30/tmt-newswire/globenewswire/novos-investigational-obesity-and-diabetes-drug-cagrisema-reduces-food-noise-and-shows-benefits-in-organ-and-bone-health-easd-2026/2436080","published":"2026-09-30T12:40:00Z","seen":"2026-09-30T12:52:37Z","lang":"en","source":{"id":"manilatimes.net","name":"manilatimes.net","domain":"manilatimes.net","outlet":{"wikidata":"Q1573100","name":"The Manila Times","type":"magazine","country":"PH","designations":["organization","periodical"]}},"via":"gdelt-gkg-english","topics":["economy","business","health","science"],"entities":[{"id":"Q818846","name":"Novo","type":"org"},{"id":"Q123427726","name":"cagrilintide/semaglutide","type":"other"}],"story":"st_nika56zngf2cerq2cc3a","category":"health","category_p":0.71,"sentiment":"positive","tone":0.04,"political":0.05},{"id":"n_nika56zngf2cerq2cc3a","seq":901287,"kind":"press_release","title":"Novo’s investigational obesity and diabetes drug CagriSema reduces ‘food noise’ and shows benefits in organ and bone health – EASD 2026","url":"https://www.globenewswire.com/news-release/2026/09/30/3371858/0/en/novo-s-investigational-obesity-and-diabetes-drug-cagrisema-reduces-food-noise-and-shows-benefits-in-organ-and-bone-health-easd-2026.html","summary":"Novo’s investigational obesity and diabetes drug CagriSema reduces ‘food noise’ and shows benefits in organ and bone health","published":"2026-09-30T12:30:00Z","seen":"2026-09-30T12:37:48Z","lang":"en","source":{"id":"globenewswire-public","name":"GlobeNewswire — public companies","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-public","topics":["business","copenhagen:novo b","dk0062498333","1492","1491"],"entities":[{"id":"Q818846","name":"Novo","type":"org"},{"id":"Q123427726","name":"cagrilintide/semaglutide","type":"other"}],"story":"st_nika56zngf2cerq2cc3a","category":"health","category_p":0.71,"sentiment":"positive","tone":0.63,"political":0.04},{"id":"n_xovrfqazq64v6r6lz44q","seq":876285,"kind":"article","title":"Ro and Novo Announce Research Collaboration to Generate First-of-its-Kind Real-World Evidence on the Wegovy® Pill","url":"http://www.prnewswire.com/news-releases/ro-and-novo-announce-research-collaboration-to-generate-first-of-its-kind-real-world-evidence-on-the-wegovy-pill-302893510.html","published":"2026-09-30T10:08:22Z","seen":"2026-09-30T10:08:22Z","lang":"en","source":{"id":"prnewswire.com","name":"prnewswire.com","domain":"prnewswire.com","outlet":{"wikidata":"Q376399","name":"PR Newswire","type":"other","country":"US","designations":["business","information resource"]}},"via":"gdelt-gkg-english","topics":["economy","health"],"authors":["Ro"],"entities":[{"id":"Q818846","name":"Novo","type":"org"},{"id":"Q133859283","name":"Wegovy","type":"other"}],"story":"st_xovrfqazq64v6r6lz44q","category":"science-technology","category_p":0.38,"category2":"health","sentiment":"positive","tone":0.58,"political":0.06},{"id":"n_533bf4xirq6tigwrqega","seq":876072,"kind":"article","title":"People switching from weight-loss injections to Novo's Wegovy® pill lost 4.1% body weight on average after three months, according to real-world data presented at EASD2026","url":"http://www.prnewswire.com/news-releases/people-switching-from-weight-loss-injections-to-novos-wegovy-pill-lost-4-1-body-weight-on-average-after-three-months-according-to-real-world-data-presented-at-easd2026--302894194.html","published":"2026-09-30T10:08:22Z","seen":"2026-09-30T10:08:22Z","lang":"en","source":{"id":"prnewswire.com","name":"prnewswire.com","domain":"prnewswire.com","outlet":{"wikidata":"Q376399","name":"PR Newswire","type":"other","country":"US","designations":["business","information resource"]}},"via":"gdelt-gkg-english","topics":["education","health","economy"],"authors":["NOVO NORDISK INC."],"entities":[{"id":"Q818846","name":"Novo","type":"org"}],"story":"st_a3b7jzzoivllypngk2eq","category":"health","category_p":0.72,"sentiment":"positive","tone":-0.19,"political":0.04},{"id":"n_a3b7jzzoivllypngk2eq","seq":875849,"kind":"article","title":"Novo's Wegovy pill improves weight loss after switch from injections","url":"https://www.cnbc.com/2026/09/30/novo-wegovy-pill-weight-loss-injections.html","published":"2026-09-30T09:45:00Z","seen":"2026-09-30T10:08:22Z","lang":"en","source":{"id":"cnbc.com","name":"cnbc.com","domain":"cnbc.com","outlet":{"wikidata":"Q1023912","name":"CNBC","type":"website","country":"US","designations":["business channel","cable channel","news website","specialty channel"]}},"via":"gdelt-gkg-english","topics":["economy","health"],"authors":["Annika Kim Constantino"],"entities":[{"id":"Q818846","name":"Novo","type":"org"},{"id":"Q133859283","name":"Wegovy","type":"other"}],"story":"st_a3b7jzzoivllypngk2eq","category":"health","category_p":0.69,"sentiment":"positive","tone":0.16,"political":0.06},{"id":"n_oy7pdesg5jji2ocohu2q","seq":849061,"kind":"article","title":"Novo Nordisk: After A 70+% Drop, It's A Great Investment (NYSE:NVO)","url":"https://seekingalpha.com/article/4950687-novo-nordisk-after-a-70-plus-percent-drop-its-a-great-investment","published":"2026-09-30T07:45:00Z","seen":"2026-09-30T07:45:16Z","lang":"en","source":{"id":"seekingalpha.com","name":"seekingalpha.com","domain":"seekingalpha.com","outlet":{"wikidata":"Q3477676","name":"Seeking Alpha","type":"other","country":"US","designations":["dot-com company"]}},"via":"gdelt-gkg-english","topics":["economy","business"],"entities":[{"id":"Q818846","name":"Novo","type":"org"}],"story":"st_oy7pdesg5jji2ocohu2q","category":"economy-business","category_p":0.67,"sentiment":"positive","tone":0.41,"political":0.03},{"id":"n_vqmwozkqin5l4uq2gzvq","seq":806345,"kind":"article","title":"To personer tiltalt for at sælge falsk Novo-lægemiddel i USA","title_en":"Two people charged with selling counterfeit Novo drug in the USA","url":"https://www.bt.dk/udland/to-personer-tiltalt-for-at-saelge-falsk-novo-laegemiddel-i-usa?referrer=RSS","summary":"To personer er tiltalt i sag om indsmugling og salg af falsk Ozempic fra Kina til amerikanske distributører.","published":"2026-09-30T00:55:47Z","seen":"2026-09-30T02:33:13Z","lang":"da","country":"DK","source":{"id":"kite-bt-dk-3131ee","name":"bt.dk","domain":"bt.dk","outlet":{"wikidata":"Q327821","name":"B.T.","type":"newspaper","designations":["daily newspaper"]}},"via":"kite-bt-dk-3131ee","topics":["udland","nyheder"],"entities":[{"id":"Q818846","name":"Novo","type":"org"}],"story":"st_36v5k5kapkzciv5b2loq","category":"crime-law","category_p":0.86,"sentiment":"negative","tone":-0.76,"political":0.11},{"id":"n_nlolztlr3kyb7wo66naq","seq":794772,"kind":"article","title":"비만·당뇨 약 패권 다툼…노보·릴리 맞불 수치로 자사 우위 주장","title_en":"Obesity and diabetes drug dominance battle... Novo and Lilly argue figures to claim company superiority","url":"https://www.pharmnews.com/news/articleView.html?idxno=306580","summary":"[팜뉴스=우정민 기자] 노보와 일라이 릴리가 자사 치료제의 우위를 다투고 있다. 차세대 비만 및 당뇨병 치료제 시장 주도권을 둘러싸고 양사는 임상 3상 성과와 간접 통계 분석, 대규모 실사용 데이터(RWE)를 각각 발표하며 정면으로 대립했다.각사가 자사 약물의 우수한 체중 감량 효과와 심혈관 혜택을 전면에 강조함에 따라 글로벌 제약 시장의 경쟁 구도가 가열되는 양상이다.노보는 주사제 임상 데이터를 통해 일라이 릴리 치료제 대비 우수한 체중 감량 성과를 제시했다. 임상 REIMAGINE 5 결과에 따르면 카그리세마(CagriSema)","published":"2026-09-30T00:22:19Z","seen":"2026-09-30T00:29:45Z","lang":"ko","source":{"id":"kite-cdn-pharmnews-com-3e2457","name":"cdn.pharmnews.com","domain":"cdn.pharmnews.com"},"via":"kite-cdn-pharmnews-com-3e2457","topics":["medicine","산업"],"authors":["우정민 기자"],"entities":[{"id":"Q818846","name":"Novo","type":"org"},{"id":"Q1073913","name":"Lilly","type":"org"}],"story":"st_nlolztlr3kyb7wo66naq","category":"economy-business","category_p":0.47,"category2":"health","sentiment":"neutral","tone":-0.19,"political":0.11}]}